Keyphrases
Antagonism
7%
Anticoagulant Therapy
5%
Anticoagulants
7%
Anticoagulation
15%
Antithrombotic Therapy
17%
Aspirin
11%
Atrial Fibrillation
100%
Bleeding
12%
Bleeding Risk
6%
Clinical Trials
7%
Clinically Significant
5%
Confidence Interval
16%
Dabigatran
10%
Direct Factors
7%
Embolism
9%
Factor Xa Inhibitors
7%
GLORIA
9%
Hazard Ratio
9%
Heart Failure
5%
High Risk
10%
International Normalized Ratio
6%
Ischemic Stroke
8%
Left Atrial Appendage
5%
Major Bleeding
8%
Myocardial Infarction
5%
Non-valvular Atrial Fibrillation
29%
Non-vitamin K Antagonist Oral Anticoagulants
8%
Novel Oral Anticoagulants
5%
Once-daily
8%
Oral Anticoagulants
5%
Oral Anticoagulation
5%
Percutaneous Coronary Intervention
7%
Randomized Trial
5%
Risk Factors
6%
Rivaroxaban
34%
Rocket
12%
ROCKET-AF
13%
Stroke Prevention
25%
Stroke Prevention in Atrial Fibrillation
7%
Stroke Risk
12%
Systemic Embolism
9%
Thromboembolism
11%
Transient Ischemic Attack
5%
Venous Thromboembolism
6%
Vitamin K
7%
Vitamin K Antagonists
15%
Warfarin
45%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
8%
Anticoagulant Agent
27%
Antiplatelet
7%
Antithrombotic Therapy
6%
Antivitamin K
16%
Atrial Fibrillation
84%
Bleeding
19%
Blood Clotting Factor 10a
7%
Cerebrovascular Accident
48%
Clinical Trial
7%
Congestive Heart Failure
10%
Dabigatran
8%
Disease
6%
Rivaroxaban
34%
Thromboembolism
10%
Venous Thromboembolism
7%
Vitamin K Group
6%
Warfarin
39%
Medicine and Dentistry
Acetylsalicylic Acid
5%
Anticoagulation
15%
Antithrombotic
20%
Antithrombotic Therapy
9%
Apoplexy
43%
Atrial Fibrillation
71%
Bleeding
8%
Brain Ischemia
6%
Cardiovascular System
7%
Congestive Heart Failure
9%
Disease
6%
Hazard Ratio
5%
Rivaroxaban
11%
Thromboembolism
12%
Vitamin K Antagonist
9%
Warfarin
15%